68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.

Sanli Y., Sanli O., Simsek D., Subramaniam R. M.

Nuclear medicine communications, cilt.39, sa.10, ss.871-880, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 10
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1097/mnm.0000000000000888
  • Dergi Adı: Nuclear medicine communications
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.871-880
  • Anahtar Kelimeler: Ga-68-PET, MRI, Ga-68-PSMA PET, CT, high-risk prostate cancer, MEMBRANE ANTIGEN-EXPRESSION, POSITRON-EMISSION-TOMOGRAPHY, ESTRO-SIOG GUIDELINES, RADICAL PROSTATECTOMY, DIAGNOSTIC-ACCURACY, EXTRACAPSULAR EXTENSION, DISEASE RECURRENCE, LYMPH-NODES, WHOLE-BODY, THERAPY
  • İstanbul Üniversitesi Adresli: Evet

Özet

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.